Biosimilar medicine authorized by the AEMPS
ACTIVE PRINCIPLE: follitropin alfa
INDICATION: Anovulation
DATE: 16/02/2015
STATUS: Authorized
MORE INFORMATION
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.
SUBSCRIBE
